Coherus Oncology (CHRS) Gross Profit (2019 - 2026)

Coherus Oncology (CHRS) has 8 years of Gross Profit data on file, last reported at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 71.78% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $31.9 million (up 46.78% YoY), and the FY2025 full-year result was $28.4 million, up 60.56% from the prior year.
• Gross Profit eased to $8.5 million in Q1 2026, from $8.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $50.7 million in Q1 2022 to a low of $869000.0 in Q1 2024.
• A 5-year average of $17.3 million and a median of $8.5 million in 2026 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit slumped 94.42% in 2024 and soared 469.16% in 2025, its largest moves.
• Tracing CHRS's Gross Profit over 5 years: stood at $31.2 million in 2022, then slumped by 77.67% to $7.0 million in 2023, then retreated by 28.37% to $5.0 million in 2024, then soared by 74.65% to $8.7 million in 2025, then dropped by 2.38% to $8.5 million in 2026.
• Business Quant data shows CHRS's Gross Profit at $8.5 million in Q1 2026, $8.7 million in Q4 2025, and $7.8 million in Q3 2025.